NPR's Ari Shapiro talks with Dr. Eric Topol of the Scripps Research Translational Institute about his concerns about the use of convalescent plasma for COVID-19 treatment.
New vaccines usually take years to get the approval of the Food and Drug Administration. But the Trump administration suggests the FDA may greenlight a coronavirus vaccine by the end of the year.
Mail-order prescriptions are another victim of recent changes to post office operations around the country. For some people, getting your mail on time could be a matter of life or death.
NPR's Ari Shapiro talks with Health and Human Services Secretary Alex Azar about the Food and Drug Administration allowing the use of convalescent plasma to treat COVID-19.
NPR takes a look at the effectiveness of convalescent plasma in treating COVID-19 and discusses a patient in Hong Kong who got infected with the coronavirus twice.
Doctors are researching why some patients remain unconscious for days or weeks, even after sedating drugs are withdrawn. They also worry that these patients aren't being given time to recover.
The president criticized the FDA this week for not giving emergency use approval to an experimental treatment for COVID-19. Scientists argue that the therapy still lacks sufficient evidence.
The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
The National Institutes of Health has asked the Food and Drug Administration to delay allowing the use of convalescent plasma to treat COVID-19 because the proof of its effectiveness is weak.
Some COVID-19 patients have mild to moderate symptoms and recover quickly, but others suffer for months. And scientists don't know why some are more susceptible to having prolonged symptoms.
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
Adjuvants play a crucial role in many vaccines' effectiveness. Some scientists say there needs to be more research into developing a wider variety of adjuvants because of how important they are.
Dr. Paul Offit, who serves on the Food and Drug Administration's vaccine advisory board, says he doesn't think an effective vaccine that's undergone adequate testing can be ready this year.
